When we founded LongeVC in 2021 and became one of the first longevity/biotech VCs worldwide, longevity was still viewed by many as speculative science—interesting research, but not yet an investable sector. That perception has fundamentally changed. Today, we are witnessing a rare convergence: demographic pressures that demand solutions, scientific tools that can finally impact aging, and AI-driven research that is cutting down timelines from decades to years. For the first time, "living longer, better" is more than a hopeful aspiration; it is a viable growth thesis.
The demographic imperative
The numbers are stark. By 2050, the global population aged 60 and older will double to 2.1 billion people, according to the World Health Organization. The number of people aged 80 and above will triple, reaching 426 million. In Japan, 30% of the population is already over 60. By the late 2070s, the global population aged 65 and older will reach 2.2 billion—surpassing the number of children under 18 for the first time in human history.
This shift is not merely a statistical curiosity; it has all the hallmarks of an economic transformation. Global life expectancy reached 73.3 years in 2024, an increase of 8.4 years since 1995. But here is the critical insight that defines our investment thesis: people are living longer, yet they are not living healthier. The healthspan-lifespan gap—the years spent burdened by disease at the end of life—has widened to 9.6 years globally and continues to grow.
Research published in JAMA Network Open in late 2024 quantified this gap across 183 countries. The findings are sobering: the gap increased by 13% over two decades, meaning we are adding more years of illness, not health, to our lives. The United States has the largest healthspan-lifespan gap of any WHO member state at 12.4 years, driven primarily by the burden of noncommunicable diseases. This creates both an economic crisis and, as bad as it may sound, an investment opportunity.
The economic strain and the opportunity
The healthcare economics are unsustainable. In the United States, as the CDC reports, 90% of the nation's $4.9 trillion in annual healthcare expenditures go to people with chronic physical and mental health conditions. Medicare beneficiaries with multiple chronic conditions account for 94% of total healthcare expenditure. Costs from cardiovascular diseases alone are projected to reach $2 trillion by 2050.
Chronic diseases are not just expensive to treat. They destroy economic productivity. The combined cost of treatment and lost wages for diabetes, cancer, and coronary issues places an extraordinary burden on individuals and healthcare systems alike.
For investors, this is a market to serve. The longevity biotech market was valued at approximately $27 billion in 2024 and is expected to reach $46 billion by 2033, growing at a compound annual growth rate of 6.5%.
Major pharmaceutical companies have taken notice. Eli Lilly publicly committed to being a longevity company at the 2024 Aging Research and Drug Discovery conference, marking a significant shift in how the pharmaceutical industry approaches aging research.
AI is compressing timelines
The drug discovery process has historically been slow and expensive—median investment to bring a new drug to market ranges from $314 million to potentially even $2.8 billion when accounting for failed trials. AI is changing this equation fundamentally.
Insilico Medicine, led by Alex Zhavoronkov, who serves as head of our advisory board, exemplifies what AI-powered longevity research looks like. Their Pharma.AI platform integrates target discovery, molecule generation, and clinical trial prediction into a unified system. Recently, Insilico Medicine, an AI-driven drug discovery company, announced a research collaboration with Eli Lilly. The partnership will combine Insilico's AI platform with Lilly's disease expertise to discover new therapies and push AI drug discovery further.
Regulatory evolution is underway
The regulations hedged around longevity remain challenging but are easing. The FDA does not currently recognize aging as a disease, which has historically complicated the approval pathway for interventions targeting aging directly. Longevity companies must target specific age-related conditions rather than aging itself.
However, significant progress is being made. The World Health Organization recently added "aging-associated decline in intrinsic capacity" to the 11th Edition of the International Classification of Diseases. Loyal, a veterinary biotech company, received FDA acceptance of "Reasonable Expectation of Effectiveness" for two drugs aimed at extending canine lifespan—the first regulatory recognition anywhere that lifespan extension is a valid therapeutic goal. If Loyal achieves approval by late 2025, it would mark the first regulatory approval of a drug intended to extend lifespan.
For human therapeutics, we see a global loosening of regulatory constraints. Montana's SB 535 bill, signed into law in May 2025, allows licensed experimental treatment centers to administer therapies after Phase I trials—the most permissive framework in the United States. Special economic zones like Próspera in Honduras are attracting longevity startups seeking streamlined approval processes for gene therapies. These developments suggest a broader trend toward regulatory sandboxes that could accelerate clinical validation of aging interventions.
As regulatory frameworks mature, we expect the pathway for longevity therapeutics to become clearer. This represents a structural tailwind for the sector.
The LongeVC perspective
Our investment thesis is straightforward: the convergence of demographic necessity, measurable biology, AI acceleration, and regulatory maturation is creating a once-in-a-generation opportunity to invest in companies that address the root causes of age-related decline.
We focus on what we call a "hard definition" of longevity—therapeutics, diagnostics, and platforms that target age-related diseases directly. This includes regenerative medicine companies like Rubedo, AI-powered skin analytics platforms like Haut.AI, early cancer detection technologies like AOA Dx, and the broader ecosystem of companies building infrastructure for precision longevity medicine.
We are direct about the challenges. Regulatory pathways remain complex. Timelines are long compared to software or consumer tech. Clinical failure rates in drug development are high. Valuations in any hot sector can become disconnected from fundamentals.
But the underlying thesis has only strengthened. People are living longer but spending more years sick. Healthcare systems cannot afford the status quo. Science has given us tools to actually measure and modify aging. And AI is compressing the timeline to therapeutic impact.
An investable future
The question is no longer whether longevity is a legitimate field of science. It is. The question is whether the companies being built today can translate that science into therapies that extend healthy human lifespan—and whether they can do so in a timeframe that rewards investors.
We believe they can. The best longevity companies combine rigorous science with strategic patience, translational thinking with regulatory savvy, and bold vision with disciplined capital allocation. These are the companies we back, and these are the companies that will define the next era of healthcare.
Because a robust, well-funded, and well-prepared longevity sector serves us all—and the ageless future it creates is worth investing in.
For more information about LongeVC and our investment approach, please contact us here.
About LongeVC
LongeVC is an international venture capital firm, based in Washington, D.C., investing in visionary biotech and longevity companies and founders. Focusing on seed and early-stage investment, LongeVC’s mission is to bring to market breakthroughs that will change lives and transform the nature of our health. LongeVC is proud to work with its highly involved and expert advisors, investors, and partners to achieve this mission and shape the future of biotech. Learn more about LongeVC and our portfolio companies at www.longevc.com.
The demographic imperative
The numbers are stark. By 2050, the global population aged 60 and older will double to 2.1 billion people, according to the World Health Organization. The number of people aged 80 and above will triple, reaching 426 million. In Japan, 30% of the population is already over 60. By the late 2070s, the global population aged 65 and older will reach 2.2 billion—surpassing the number of children under 18 for the first time in human history.
This shift is not merely a statistical curiosity; it has all the hallmarks of an economic transformation. Global life expectancy reached 73.3 years in 2024, an increase of 8.4 years since 1995. But here is the critical insight that defines our investment thesis: people are living longer, yet they are not living healthier. The healthspan-lifespan gap—the years spent burdened by disease at the end of life—has widened to 9.6 years globally and continues to grow.
Research published in JAMA Network Open in late 2024 quantified this gap across 183 countries. The findings are sobering: the gap increased by 13% over two decades, meaning we are adding more years of illness, not health, to our lives. The United States has the largest healthspan-lifespan gap of any WHO member state at 12.4 years, driven primarily by the burden of noncommunicable diseases. This creates both an economic crisis and, as bad as it may sound, an investment opportunity.
The economic strain and the opportunity
The healthcare economics are unsustainable. In the United States, as the CDC reports, 90% of the nation's $4.9 trillion in annual healthcare expenditures go to people with chronic physical and mental health conditions. Medicare beneficiaries with multiple chronic conditions account for 94% of total healthcare expenditure. Costs from cardiovascular diseases alone are projected to reach $2 trillion by 2050.
Chronic diseases are not just expensive to treat. They destroy economic productivity. The combined cost of treatment and lost wages for diabetes, cancer, and coronary issues places an extraordinary burden on individuals and healthcare systems alike.
For investors, this is a market to serve. The longevity biotech market was valued at approximately $27 billion in 2024 and is expected to reach $46 billion by 2033, growing at a compound annual growth rate of 6.5%.
Major pharmaceutical companies have taken notice. Eli Lilly publicly committed to being a longevity company at the 2024 Aging Research and Drug Discovery conference, marking a significant shift in how the pharmaceutical industry approaches aging research.
AI is compressing timelines
The drug discovery process has historically been slow and expensive—median investment to bring a new drug to market ranges from $314 million to potentially even $2.8 billion when accounting for failed trials. AI is changing this equation fundamentally.
Insilico Medicine, led by Alex Zhavoronkov, who serves as head of our advisory board, exemplifies what AI-powered longevity research looks like. Their Pharma.AI platform integrates target discovery, molecule generation, and clinical trial prediction into a unified system. Recently, Insilico Medicine, an AI-driven drug discovery company, announced a research collaboration with Eli Lilly. The partnership will combine Insilico's AI platform with Lilly's disease expertise to discover new therapies and push AI drug discovery further.
Regulatory evolution is underway
The regulations hedged around longevity remain challenging but are easing. The FDA does not currently recognize aging as a disease, which has historically complicated the approval pathway for interventions targeting aging directly. Longevity companies must target specific age-related conditions rather than aging itself.
However, significant progress is being made. The World Health Organization recently added "aging-associated decline in intrinsic capacity" to the 11th Edition of the International Classification of Diseases. Loyal, a veterinary biotech company, received FDA acceptance of "Reasonable Expectation of Effectiveness" for two drugs aimed at extending canine lifespan—the first regulatory recognition anywhere that lifespan extension is a valid therapeutic goal. If Loyal achieves approval by late 2025, it would mark the first regulatory approval of a drug intended to extend lifespan.
For human therapeutics, we see a global loosening of regulatory constraints. Montana's SB 535 bill, signed into law in May 2025, allows licensed experimental treatment centers to administer therapies after Phase I trials—the most permissive framework in the United States. Special economic zones like Próspera in Honduras are attracting longevity startups seeking streamlined approval processes for gene therapies. These developments suggest a broader trend toward regulatory sandboxes that could accelerate clinical validation of aging interventions.
As regulatory frameworks mature, we expect the pathway for longevity therapeutics to become clearer. This represents a structural tailwind for the sector.
The LongeVC perspective
Our investment thesis is straightforward: the convergence of demographic necessity, measurable biology, AI acceleration, and regulatory maturation is creating a once-in-a-generation opportunity to invest in companies that address the root causes of age-related decline.
We focus on what we call a "hard definition" of longevity—therapeutics, diagnostics, and platforms that target age-related diseases directly. This includes regenerative medicine companies like Rubedo, AI-powered skin analytics platforms like Haut.AI, early cancer detection technologies like AOA Dx, and the broader ecosystem of companies building infrastructure for precision longevity medicine.
We are direct about the challenges. Regulatory pathways remain complex. Timelines are long compared to software or consumer tech. Clinical failure rates in drug development are high. Valuations in any hot sector can become disconnected from fundamentals.
But the underlying thesis has only strengthened. People are living longer but spending more years sick. Healthcare systems cannot afford the status quo. Science has given us tools to actually measure and modify aging. And AI is compressing the timeline to therapeutic impact.
An investable future
The question is no longer whether longevity is a legitimate field of science. It is. The question is whether the companies being built today can translate that science into therapies that extend healthy human lifespan—and whether they can do so in a timeframe that rewards investors.
We believe they can. The best longevity companies combine rigorous science with strategic patience, translational thinking with regulatory savvy, and bold vision with disciplined capital allocation. These are the companies we back, and these are the companies that will define the next era of healthcare.
Because a robust, well-funded, and well-prepared longevity sector serves us all—and the ageless future it creates is worth investing in.
For more information about LongeVC and our investment approach, please contact us here.
About LongeVC
LongeVC is an international venture capital firm, based in Washington, D.C., investing in visionary biotech and longevity companies and founders. Focusing on seed and early-stage investment, LongeVC’s mission is to bring to market breakthroughs that will change lives and transform the nature of our health. LongeVC is proud to work with its highly involved and expert advisors, investors, and partners to achieve this mission and shape the future of biotech. Learn more about LongeVC and our portfolio companies at www.longevc.com.